1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

FTC clears Takeda’s acquisition of Shire

Discussion in 'Pharma/Biotech Comp - Gen Discussion |Pharma Sales' started by RobertPhillips900, Jul 10, 2018 at 9:42 AM.

  1. RobertPhillips900

    Joined:
    Aug 29, 2016
    Messages:
    51
    Likes Received:
    0
    The US Federal Trade Commission (FTC) has given its nod for the proposed $62 billion acquisition of Shire (SHPG) by Japanese firm Takeda Pharmaceuticals. The merger, the largest ever by a Japanese company, was cleared sans any conditions. Takeda plans to close the acquisition during the first half of next year.

    https://news.alphastreet.com/ftc-clears-takedas-acquisition-of-shire/